![]() | |
Clinical data | |
---|---|
Other names | RG-7906; RO-6889450 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C17H22N4O2 |
Molar mass | 314.389 g·mol−1 |
3D model ( JSmol) | |
| |
|
Ralmitaront ( INN , USAN ; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which is undergoing a clinical trial for the treatment of negative symptoms in schizophrenia and schizoaffective disorder. [1] [2] [3] Another clinical trial targeting acute psychotic symptoms of schizophrenia has been terminated due to lack of efficacy. [4] It is a partial agonist of the TAAR1. [5] The medication is being developed by the pharmaceutical company Hoffmann-La Roche. [1] Ralmitaront had completed phase 1 clinical trials. [1] [6]